Skip to main content
PlainMeds

Prescription medicine

Human hepatitis b virus immune globulin Brand names: Nabi-Hb

Human hepatitis b virus immune globulin (Nabi-Hb) is a prescription medicine. No generic is listed in FDA's NDC Directory.

  • No generic listed

Check it at the source: the human hepatitis b virus immune globulin FDA label on DailyMed (effective April 10, 2025); every human hepatitis b virus immune globulin label on DailyMed.

Highlights of the record

FDA label of April 10, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage

Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infec- tion in the following settings: Acute Exposure to Blood Containing HBsAg: Following either parenteral exposure (needlestick, bite, sharps), di

Forms and strengths

  • 5ml

Liquid.

On the market

Generic approvals
No generic approved
Labelers listed (NDC)
1 of which 0 under generic applications, 1 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC)
Not in the survey
Shortage (FDA)
No current entry
Recalls by its makers (FDA)
No recall recorded
FAERS reports
51 through July 30, 2026

What is human hepatitis b virus immune globulin used for?

From the label: indications and usage

Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infec- tion in the following settings: Acute Exposure to Blood Containing HBsAg: Following either parenteral exposure (needlestick, bite, sharps), direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident), involving HBsAg-positive materials such as blood, plasma, or serum. […]

Conditions named in the indications of human hepatitis b virus immune globulin's FDA labels, with every medicine labeled for each:

From other human hepatitis b virus immune globulin labels

Hepatitis B: Household Exposure to Persons with Acute HBV Infection:

FDA pharmacologic class: Human Immunoglobulin.

Source: FDA drug label (Nabi-HB), ADMA Biologics, Inc., effective April 10, 2025 (SPL set 47fe1a99-5078-4b89-84fa-9e8387baec5c), via openFDA; the full label on DailyMed

Is there a generic for human hepatitis b virus immune globulin (Nabi-Hb)?

No generic human hepatitis b virus immune globulin is approved (Drugs@FDA, October 8, 2026).

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do FAERS reports show for human hepatitis b virus immune globulin?

The FDA Adverse Event Reporting System holds 51 reports that list human hepatitis b virus immune globulin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 8 are coded as a death and 17 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

  • Expired Product Administered (a use or a product term, not a reaction)5
  • Renal Failure4
  • Drug Ineffective (a use or a product term, not a reaction)3
  • Liver Function Test Abnormal3
  • Multi-Organ Failure3
  • Off Label Use (a use or a product term, not a reaction)3
  • Sepsis3
  • Acute Respiratory Distress Syndrome2

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Human hepatitis b virus immune globulin side effects
the label's list beside FAERS reports
Check an interaction
what two or more labels say about each other